21 Sep 2018 14:19
Additional listing
21 September 2018
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has today issued and allotted 1,000,000 new ordinary shares of 5p each ("New Ordinary Shares") following the exercise of share options under the EMI Scheme.
Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 27 September 2018. The New Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.
The total number of ordinary shares of 5p each in issue, following admission of the New Ordinary Shares, will be 71,069,933. The Company holds no shares in Treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Silence Therapeutics plc Dr David Horn Solomon, Chief Executive Officer Dr Andy Richards, CBE, Interim Chair David Ellam, Chief Financial Officer
| Tel: +44 (0) 20 3457 6900 |
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/ Oliver Jackson
| Tel: +44 (0) 20 7418 8900 |
European IR Consilium Strategic Communications Mary-Jane Elliot/ Angela Gray silencetherapeutics@consilium-comms.com
| Tel: +44 (0) 20 3709 5700 |
US IR Burns McClellan Lisa Burns, John Grimaldi, Jill Steier Silence.Therapeutics@burnsmc.com | Tel: +1 (212) 213 0006 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: https://www.silence-therapeutics.com/
SLN.L (SLN)